 |
3 Diseases |  |
5 Trials |
|
5 Trials |  |
20 News |  |
| «12 |
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Apr 22, 2021
P2, N=46, Not yet recruiting, Sponsor: Henan Cancer Hospital
N=71 --> 46 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Dec 2021 --> Apr 2022
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Dec 22, 2020
P2, N=71, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 26, 2020
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
N=71 --> 46 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Dec 2021 --> Apr 2022 Trial completion date: Jul 2020 --> Jun 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer?NSCLC? (clinicaltrials.gov) - Jul 14, 2020
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Trial completion date: Jul 2020 --> Jun 2021 | Trial primary completion date: Apr 2020 --> Apr 2021 Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 9, 2019
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020 Not yet recruiting --> Recruiting
- ||||||| utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion, Combination therapy, Metastases: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Apr 19, 2019
P3, N=405, Completed, Sponsor: Beijing Biostar Technologies, Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Trial initiation date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer?NSCLC? (clinicaltrials.gov) - Apr 9, 2019
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Mar 2019
- || utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 8, 2019
P2, N=30, Not yet recruiting, Sponsor: Beijing Biostar Technologies, Ltd
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer?NSCLC? (clinicaltrials.gov) - Oct 2, 2018
P2, N=30, Not yet recruiting, Sponsor: Beijing Biostar Technologies, Ltd
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Combination therapy, Metastases: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Aug 1, 2018
P3, N=405, Active, not recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Mar 2019 Trial completion date: Dec 2017 --> Dec 2018
- |||| utidelone IV (UTD1) / Beijing Biostar Technologies
Trial primary completion date, Combination therapy, Metastases: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Mar 8, 2017
P3, N=405, Active, not recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Sep 2016
- ||||| utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment closed, Enrollment change, Combination therapy, Metastases: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Jan 21, 2016
P3, N=405, Active, not recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Trial primary completion date: Dec 2016 --> Sep 2016 Recruiting --> Active, not recruiting | N=290 --> 405
- || utidelone IV (UTD1) / Beijing Biostar Technologies
New P3 trial, Combination therapy, Metastases: Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer (clinicaltrials.gov) - Oct 2, 2014
P3, N=290, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd